Novartis’s MS Franchise Setback For Ofatumumab In US
FDA Extends Review Time To September 2020
Novartis will not start to compete in the increasingly crowded US multiple sclerosis marketplace with ofatumumab this month, as regulators extend the review process for the B-cell depleting therapy until September.
